Cargando…
Cellular Therapies in Pediatric Liver Diseases
Liver transplantation is the gold standard for the treatment of pediatric end-stage liver disease and liver based metabolic disorders. Although liver transplant is successful, its wider application is limited by shortage of donor organs, surgical complications, need for life long immunosuppressive m...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406752/ https://www.ncbi.nlm.nih.gov/pubmed/36010561 http://dx.doi.org/10.3390/cells11162483 |
_version_ | 1784774198014509056 |
---|---|
author | Vimalesvaran, Sunitha Nulty, Jessica Dhawan, Anil |
author_facet | Vimalesvaran, Sunitha Nulty, Jessica Dhawan, Anil |
author_sort | Vimalesvaran, Sunitha |
collection | PubMed |
description | Liver transplantation is the gold standard for the treatment of pediatric end-stage liver disease and liver based metabolic disorders. Although liver transplant is successful, its wider application is limited by shortage of donor organs, surgical complications, need for life long immunosuppressive medication and its associated complications. Cellular therapies such as hepatocytes and mesenchymal stromal cells (MSCs) are currently emerging as an attractive alternative to liver transplantation. The aim of this review is to present the existing world experience in hepatocyte and MSC transplantation and the potential for future effective applications of these modalities of treatment. |
format | Online Article Text |
id | pubmed-9406752 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94067522022-08-26 Cellular Therapies in Pediatric Liver Diseases Vimalesvaran, Sunitha Nulty, Jessica Dhawan, Anil Cells Review Liver transplantation is the gold standard for the treatment of pediatric end-stage liver disease and liver based metabolic disorders. Although liver transplant is successful, its wider application is limited by shortage of donor organs, surgical complications, need for life long immunosuppressive medication and its associated complications. Cellular therapies such as hepatocytes and mesenchymal stromal cells (MSCs) are currently emerging as an attractive alternative to liver transplantation. The aim of this review is to present the existing world experience in hepatocyte and MSC transplantation and the potential for future effective applications of these modalities of treatment. MDPI 2022-08-10 /pmc/articles/PMC9406752/ /pubmed/36010561 http://dx.doi.org/10.3390/cells11162483 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Vimalesvaran, Sunitha Nulty, Jessica Dhawan, Anil Cellular Therapies in Pediatric Liver Diseases |
title | Cellular Therapies in Pediatric Liver Diseases |
title_full | Cellular Therapies in Pediatric Liver Diseases |
title_fullStr | Cellular Therapies in Pediatric Liver Diseases |
title_full_unstemmed | Cellular Therapies in Pediatric Liver Diseases |
title_short | Cellular Therapies in Pediatric Liver Diseases |
title_sort | cellular therapies in pediatric liver diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406752/ https://www.ncbi.nlm.nih.gov/pubmed/36010561 http://dx.doi.org/10.3390/cells11162483 |
work_keys_str_mv | AT vimalesvaransunitha cellulartherapiesinpediatricliverdiseases AT nultyjessica cellulartherapiesinpediatricliverdiseases AT dhawananil cellulartherapiesinpediatricliverdiseases |